Kanis J A
WHO Collaborating Centre for Metabolic Bone Disease, University of Sheffield Medical School, UK.
Osteoporos Int. 1994 Nov;4(6):368-81. doi: 10.1007/BF01622200.
The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women. The disease is common and readily diagnosed by the measurement of bone mineral with single- or dual-energy absorptiometry. Such measurements have high specificity but lower sensitivity, so that the value of the technique is greater for those identified as being at higher risk. Against this background there is little evidence that osteoporosis can usefully be tackled by a public health policy to influence risk factors such as smoking, exercise and nutrition. This suggests that it is appropriate to consider targetting of treatment with agents affecting bone metabolism to susceptible individuals. Since the main benefits of the use of hormone replacement therapy (HRT) are probably on cardiovascular morbidity, the major role for selective screening is to direct non-HRT interventions. An appropriate time to consider screening and intervention is at the menopause, but screening at later ages is also worthy of consideration. Since the cost of screening is low and that of bone-active drugs is high, the selective use of screening techniques will improve the cost-benefit ratio of intervention.
在白种女性中,很大程度上满足了骨质疏松症有效筛查策略所需的标准。这种疾病很常见,通过单能或双能吸收测定法测量骨矿物质可轻易诊断。此类测量具有高特异性但敏感性较低,因此该技术对那些被确定为高风险人群的价值更大。在此背景下,几乎没有证据表明通过公共卫生政策来影响诸如吸烟、运动和营养等风险因素能有效应对骨质疏松症。这表明考虑针对易患个体使用影响骨代谢的药物进行治疗是合适的。由于使用激素替代疗法(HRT)的主要益处可能在于心血管疾病发病率方面,选择性筛查的主要作用是指导非HRT干预措施。考虑筛查和干预的合适时间是在绝经时,但在更高年龄时进行筛查也值得考虑。由于筛查成本低而骨活性药物成本高,选择性使用筛查技术将提高干预措施的成本效益比。